Janecluc

Metformin Hydrochloride and Sitagliptin, the active ingredient in Janecluc, is a Biguanide; DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults.

GNH USA supplies Janecluc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Janecluc is an oral antidiabetic combination that targets hyperglycaemia in type 2 diabetes mellitus.

- Type 2 diabetes mellitus (initial therapy): provides improved glycaemic control as first‑line treatment. - Type 2 diabetes mellitus (add‑on therapy): enhances glucose lowering when metformin alone is insufficient. - Type 2 diabetes mellitus (dual therapy): offers combined biguanide and DPP‑4 inhibition for patients requiring multiple mechanisms of action.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or flatulence. - Diarrhoea: loose stools occurring especially after dose initiation. - Headache: mild to moderate intensity. - Upper respiratory tract infection: cold‑like symptoms. - Fatigue: feeling of tiredness without exertion.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: marked elevation of liver enzymes.

Before initiating Janecluc, clinicians should assess patient suitability and monitor for adverse outcomes. - Renal function: evaluate eGFR and avoid use in severe renal impairment. - Hepatic status: check liver enzymes; use cautiously in hepatic disease. - Risk of lactic acidosis: avoid in conditions predisposing to hypoxia. - Elderly patients: start at lower dose and monitor tolerance. - Concomitant medications: review for drugs that may affect glucose levels. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Janecluc may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate renal failure, increasing metformin accumulation. - Cimetidine: raises sitagliptin plasma concentrations, heightening risk of side effects. - Rifampin: markedly reduces sitagliptin exposure, diminishing efficacy.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors or ARBs: combined effect on renal function warrants monitoring. - NSAIDs: can impair renal function, increasing metformin levels. - Alcohol: potentiates risk of lactic acidosis. - Beta‑blockers: may mask hypoglycaemia symptoms.